Antibodies: The key to spatial mass spectrometry success
Multiplex immunohistochemistry (IHC) techniques allow multiple proteins to be visualized in the tissue leading to the identification of cell phenotypes, which can help gain an understanding of the spatial arrangement of cells within a tumor. Each multiplex IHC method places unique challenges upon antibody performance. For example, tyramide signal amplification (TSA)-based multiplex immunofluorescence assays (mIF) require optimization of staining order, while antibody performance can become compromised after metal conjugation during imaging mass spectrometry.
In this webinar, join Mike Spencer, senior director of antibody validation and IHC at Fortis Life Sciences, as he explores effective strategies to ensure optimal antibody performance in multiplex IHC assays.
Key learning objectives
- Learn how poor antibody performance can impact multiplex IHC assay results
- Understand how different multiplex IHC platforms come with their own set of unique challenges
- Discover how to efficiently screen antibodies for imaging mass spectrometry
Who should attend?
Scientists interested in multiplex IHCTranslational researchers studying the tumor microenvironmentResearchers studying immunooncology using imaging mass spectrometryScientists studying tumor infiltrating lymphocytes
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.